SCHEMBL2629582

SCHEMBL2629582

CC(C)(C)C(=O)OCC1O[C@@H](OCc2ccccc2)C(O)[C@@H](OC(=O)C(C)(C)C)[C@@H]1F

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LGALS8 O00214 1/20 0.42
▸ NT5E P21589 1/20 0.39
▸ SLC6A2 P23975 1/20 0.36
▸ POLB P06746 1/20 0.36
▸ FGF1 P05230 2/20 0.36
▸ FGF2 P09038 2/20 0.36
▸ VEGFA P15692 2/20 0.36
▸ HPSE Q9Y251 2/20 0.36
▸ LMNA P02545 2/20 0.36
▸ TACR2 P21452 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ SSTR5 P35346 2/20 0.35
▸ SSTR1 P30872 1/20 0.35
▸ SSTR2 P30874 1/20 0.35
▸ SSTR4 P31391 1/20 0.35
▸ SSTR3 P32745 1/20 0.35
▸ CYP2D6 P10635 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ MAPK1 P28482 1/20 0.35
▸ PRKCA P17252 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14075626 1.00 LGALS8 (0.42) LGALS8NT5ESLC6A2POLBFGF1
SCHEMBL472852 1.00 LGALS8 (0.42) LGALS8NT5ESLC6A2POLBFGF1
SCHEMBL472853 0.91 NT5E (0.44) NT5EPOLBFGF1FGF2VEGFA
SCHEMBL14075622 0.91 LGALS8 (0.48) LGALS8NT5ESLC6A2POLBFGF1
SCHEMBL2629592 0.91 LGALS8 (0.48) LGALS8NT5ESLC6A2POLBFGF1
SCHEMBL14409788 0.91 LGALS8 (0.48) LGALS8NT5ESLC6A2POLBFGF1
SCHEMBL10077888 0.88 LGALS8 (0.37) LGALS8NT5ESLC6A2POLBFGF1
SCHEMBL472876 0.85 FGF1 (0.37) LGALS8NT5EPOLBFGF1FGF2
SCHEMBL13695054 0.84 NT5E (0.36) LGALS8NT5EPOLBFGF1FGF2
SCHEMBL14075625 0.84 NT5E (0.36) LGALS8NT5EPOLBFGF1FGF2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8158763-B2 Lipophilic protected, asparagine-linked oligosaccharide derivative containing a fucose in N-acetylglucosamine on nonreducing terminal side Kajihara, Yasuhiro (JP) 2012-04-17 — — US disclosed
US-8063202-B2 Process for preparing glycopeptides having asparagine-linked oligosaccharides, and the glycopeptides OTSUKA CHEMICAL CO., LTD. (JP) 2011-11-22 — — US disclosed
US-7943763-B2 Process for preparing glycopeptides having asparagine-linked oligosaccharides, and the glycopeptides OTSUKA CHEMICAL HOLDINGS CO., LTD. (JP) 2011-05-17 — — US disclosed
US-20090234095-A1 Process for preparing glycopeptides having asparagine-linked oligosaccharides, and the glycopeptides GLYTECH, INC. (JP) 2009-09-17 — — US disclosed
US-7304148-B2 Sugar chain asparagine derivatives, sugar chain asparagine, sugar chain, and processes for producing these OTSUKA CHEMICAL CO., LTD. (JP) 2007-12-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090234095-A1 Process for preparing glycopeptides having asparagine-linked oligosaccharides, and the glycopeptides ASNS, ANPEP, B3GNT2 LGALS8 147/4885NT5E 325/4885SLC6A2 2096/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback